ECONOMIC VALUE DRIVERS IN SEVERE RED BLOOD CELL DISORDERS- A REVIEW AND DEVELOPMENT OF AN ECONOMIC CONCEPTUAL FRAMEWORK

Author(s)

Tremblay G1, Lemay W2
1Purple Squirrel Economics, New York, NY, USA, 2Purple Squirrel Economics, Montreal, QC, Canada

Presentation Documents

OBJECTIVES : Anemia treatments have greatly improved patient life expectancy in the past decade. However, few economic studies have evaluated the budgetary impact and cost effectiveness of these new therapies. The purpose of this study is to review published economic studies in severe red blood cell disorders, including autoimmune hemolytic anemia, beta-thalassemia, chemotherapy-induced anemia, chronic kidney disease anemia, and severe aplastic anemia to inform the conceptual framework for future economic research in severe anemia.

METHODS : Economic literature for the various types of anemia was reviewed by a targeted search. The review considered cost-effectiveness analyses (CEA), cost-utility analyses (CUA), and budget impact models (BIM) and evaluated the main assumptions impacting their validity. Primarily, the assumptions assessed included the model structure (decision tree, Markov model), the time horizon, the perspective, and the included costs. Based on these assessments, an optimal conceptual framework was proposed for future economic research, accounting for the criteria used previously.

RESULTS

:
A total of eleven studies were analyzed: five CEAs, four BIMs, and two CUA. The studies were predominantly from G8 countries. The time horizon varied significantly from 15 weeks to lifetime, which is important as smaller timeframes do not take into consideration the long-term impact of treatment outcomes. Additionally, the types of costs included varied among studies, and mortality costs were rarely included. Furthermore, the association between serum ferritin and mortality was neglected in most of the studies considering adverse events. Lastly, uncertainty was not always assessed properly, particularly for lifetime models.

CONCLUSIONS : The economic analyses found in red blood cell disorders seem to overlook core elements, particularly the included costs. Importantly, adverse events, administration, and mortality costs were not calculated in most of the studies. The conceptual framework proposed will help identify and reduce gaps related to economic model conceptualization in red blood cell disorders.

Conference/Value in Health Info

2020-05, ISPOR 2020, Orlando, FL, USA

Code

PSY5

Topic

Economic Evaluation

Disease

Systemic Disorders/Conditions

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×